Ranbaxy Laboratories' wholly owned subsidiary Ranbaxy Pharmaceuticals Canada Inc. (RPCI), has received an approval on December 24, 2013 to manufacture and market RAN-Donepezil Hydrochloride 5 mg and 10 mg tablets from Health Canada.
The total market size of Aricept (Donepezil Hydrochloride) in Canada is $153.9 million and growing at 38% (extended units). Donepezil Hydrochloride is indicated in the treatment of dementia in Alzheimer’s patients.
Ranbaxy Pharmaceuticals Canada Inc. (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of Ranbaxy Laboratories, India’s largest pharmaceutical company. RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.
The total market size of Aricept (Donepezil Hydrochloride) in Canada is $153.9 million and growing at 38% (extended units). Donepezil Hydrochloride is indicated in the treatment of dementia in Alzheimer’s patients.
Ranbaxy Pharmaceuticals Canada Inc. (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of Ranbaxy Laboratories, India’s largest pharmaceutical company. RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.
No comments:
Post a Comment